7 results about "T-lymphocyte proliferation" patented technology

This invention belongs to the field of plant extract technology, specifically relating to a plant extract composition for enhancing immunity. By weight, it is composed of the following raw materials: 3-5 parts Astragalus membranaceus extract, 2.5-4 parts Echinacea purpurea extract, and 1.5-3.5 parts Rhodiola rosea extract. This plant extract composition, through the scientific formulation of Astragalus membranaceus, Echinacea purpurea, and Rhodiola rosea, and an enzymatic extraction process, enhances the immunomodulatory effect. The combination of the three extracts increases the secretion of TNF-α and IL-6 by macrophages. Furthermore, the spleen lymphocyte stimulation index (SI) of the three extracts reaches 5.57, and the lymphocyte transformation rate increases from 191% to 457%. These results indicate that this plant extract composition effectively enhances the body's non-specific and cellular immune functions by activating macrophages and promoting T lymphocyte proliferation through multiple pathways, providing more comprehensive immune protection.

The application discloses a Rhododendron molle flower extract with immunosuppressive activity and a preparation method and application thereof. The Rhododendron molle flower extract is prepared by taking dried flower powder of Rhododendron molle as raw material and 95% ethanol as an extracting agent under the following conditions: condensation reflux extraction for 2 hours at 60 DEG C and a material-liquid ratio of 1:10. The extract is filtered and collected, and the above extract is combined and concentrated under vacuum and reduced pressure to obtain the Rhododendron molle flower extract. The extract has an inhibitory rate of 61.41% on T lymphocyte proliferation induced by abrin and an inhibitory rate of 51.54% on B lymphocyte proliferation induced by lipopolysaccharide at a concentration of 100 mg / mL, and has no cytotoxicity on normal mouse spleen lymphocytes. The application provides a candidate research material for researching and developing a new immunosuppressant, and provides a scientific basis for developing and utilizing the Rhododendron molle resources.

The invention discloses a brucella-tubercle bacillus bigeminy recombinant vaccine based on an outer membrane protein OMP31 and application of the brucella-tubercle bacillus bigeminy recombinant vaccine, and belongs to the technical field of biological medicines. The invention aims at developing a brucella-tubercle bacillus bivalent vaccine, based on a brucella OMP31 gene and a tuberculosis vaccine strain bacillus calmette guerin (rBCG) vector, gene recombination is carried out, a recombinant vector is constructed, and the immune protection effect of mice is verified. According to the invention, the recombinant BCG vaccine rBCG-OMP31 is successfully constructed, and the recombinant BCG strain grows well; after a mouse is immunized, T lymphocyte proliferation is promoted, an immune state dominated by Th1 type immune response is formed, and the immune protection effect of the mouse can be remarkably improved. Therefore, data support is provided for developing safe and effective Brucella BCG vector candidate vaccines.

A method for increasing dendritic cell migration ability, and a use thereof are disclosed. A method according to one aspect can increase the migration ability of mature dendritic cells and increase the induction, by dendritic cells, of inflammatory cytokine production, T lymphocyte proliferation and T lymphocyte polarization, and thus can be used for the prevention or treatment of immune-related diseases.

This invention provides a mutant S protein of porcine transmissible gastroenteritis virus (TGEV), a subunit vaccine, and its application; the amino acid sequence of the S protein mutant is shown in SEQ ID NO.3. The S protein mutant of TGEV constructed by this invention is significantly superior to the wild-type SWT protein in both humoral and cellular immunity, and its protein expression level also shows a clear advantage, demonstrating excellent prospects for subunit vaccine development and application. Specifically, in terms of immunity, after the S protein mutant is formulated into a vaccine, this invention can enhance post-immunization antibody levels, TGEV virus neutralizing antibody titers, cellular immune responses, and T lymphocyte proliferation.

The invention discloses a method for evaluating maturation and functional damage of CIAV virus to chicken bone marrow-derived dendritic cells, and belongs to the technical field of virus immunology. The method comprises the following steps: separating and culturing chicken bone marrow-derived dendritic cells in vitro, stimulating the chicken bone marrow-derived dendritic cells by using a CIAV virus, and detecting the phagocytic function of the cells, the expression of surface marker molecules CD40 and MHC II, the secretion level of cell factors IFN-beta, IL-10 and IL-12, and the induction capability of the dendritic cells on the proliferation of allogeneic T lymphocytes. And comprehensively evaluating the damage effect of the CIAV virus on the maturation, differentiation and function of the dendritic cells. The method is standard in operation and reliable in result, an effective tool is provided for deeply researching a CIAV-mediated natural immunosuppression mechanism, and meanwhile, a scientific basis is provided for development of a CIAV prevention and control strategy.

The invention provides an S protein mutant of a swine transmissible gastroenteritis virus, a subunit vaccine and application. The amino acid sequence of the S protein mutant is as shown in SEQ ID NO. 3. The S protein mutant of the swine transmissible gastroenteritis virus constructed by the invention is obviously superior to an SWT wild type protein in humoral immunity and cellular immunity, and the protein expression quantity also shows an obvious advantage, so that the S protein mutant has a very good subunit vaccine research, development and application prospect; specifically, in the aspect of immunization, after the S protein mutant is prepared into a vaccine, the post-immunization antibody level, the TGEV virus neutralizing antibody titer, the cellular immune response and the T lymphocyte proliferation effect can be improved.